Table 1 Summary of clinical and molecular data of lower-grade gliomas in the study
From: TERT promoter mutations contribute to subset prognostication of lower-grade gliomas
| Â | Â | Â | Â | Â | Â | TERT promoter mutation | IDH mutation | Â | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Diagnosis | N | Male | Mean age (years) | Median PFS (months) | Median OS (months) | C228T | C250T | Combined % | IDH1 | IDH2 | Combined % | 1p/19q codeletion (%) |
Diffuse astrocytoma | 105 | 60% | 39.9 | 65.3 | 101.2 | 12 | 4 | 15% | 69 | 2 | 68% | 7% |
Anaplastic astrocytoma | 63 | 76% | 43.3 | 16 | 22 | 12 | 4 | 25% | 26 | 1 | 43% | 0% |
Oligodendroglioma | 18 | 44% | 41.2 | 108 | NR | 7 | 6 | 72% | 17 | 0 | 94% | 59% |
Anaplastic oligodendroglioma | 3 | 33% | 50.7 | 24 | 24 | 2 | 1 | 100% | 3 | 0 | 100% | 67% |
Oligoastrocytoma | 45 | 51% | 37.2 | NR | 120.6 | 10 | 7 | 38% | 34 | 3 | 82% | 41% |
Anaplastic oligoastrocytoma | 3 | 67% | 38 | 19.6 | 37.2 | 1 | 1 | 67% | 2 | 1 | 100% | 0% |
